Inventory	12 Months Ended
Mar. 04, 2023
Inventory
Inventory	12. Inventory As of March 4, 2023 and February 26, 2022, inventories were $539,932 and $487,173, respectively, lower than the amounts that would have been reported using the first-in, first-out (“FIFO”) cost flow assumption. The Company calculates its FIFO inventory valuation using the retail method for store inventories and the cost method for distribution facility inventories. The Company recorded a LIFO charge of $53,028 and $1,314, for fiscal year 2023 and 2022, respectively, and a LIFO credit of $51,692 for fiscal year 2021. During fiscal 2023, 2022 and 2021, a reduction in non-pharmacy inventories resulted in the liquidation of applicable LIFO inventory quantities carried at lower costs in prior years. This LIFO liquidation resulted in a $31,857, $13,090 and $26,861 cost of revenues decrease, with a corresponding reduction to the adjustment to LIFO for fiscal 2023, fiscal 2022 and fiscal 2021, respectively.

Inventory

12 Months Ended

Mar. 04, 2023

12. Inventory

As of March 4, 2023 and February 26, 2022, inventories were $539,932 and $487,173, respectively, lower than the amounts that would have been reported using the first-in, first-out (“FIFO”) cost flow assumption. The Company calculates its FIFO inventory valuation using the retail method for store inventories and the cost method for distribution facility inventories. The Company recorded a LIFO charge of $53,028 and $1,314, for fiscal year 2023 and 2022, respectively, and a LIFO credit of $51,692 for fiscal year 2021. During fiscal 2023, 2022 and 2021, a reduction in non-pharmacy inventories resulted in the liquidation of applicable LIFO inventory quantities carried at lower costs in prior years. This LIFO liquidation resulted in a $31,857, $13,090 and $26,861 cost of revenues decrease, with a corresponding reduction to the adjustment to LIFO for fiscal 2023, fiscal 2022 and fiscal 2021, respectively.